Circulating serum sVCAM-1 concentration in advanced ovarian cancer patients: correlation with concentration in ascites

Jakimovska, Marina; Černe, Katarina; Verdenik, Ivan; Kobal, Borut

doi:10.2478/raon-2013-0066

Cited by 9 publications

(17 citation statements)

References 28 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One small cohort study of 36 ovarian cancer patients identified significantly elevated sVCAM-1 in 5 patients who died within 11 months of follow-up compared to the 31 who were alive (27). Another report found no association between sVCAM-1 and outcome among ovarian cancer patients (n=50) but was able to identify patients with metastatic disease (28).…”

Section: Discussionmentioning

confidence: 99%

“…patients who died within 11 months of follow-up compared with the 31 who were alive. 27 Another study found no association between sVCAM-1 and outcome among ovarian cancer patients (n 5 50) but identified patients with metastatic disease. 28 The primary objective of our study was to link sVCAM-1 to mesothelium VCAM-1 expression with the expectation that it could serve as a surrogate prognosticator.…”

Section: Vcam-1 and Ovarian Cancer Outcome/scalici Et Almentioning

confidence: 96%

See 1 more Smart Citation

Mesothelium expression of vascular cell adhesion molecule‐1 (VCAM‐1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC)

Scalici

Arapovic

Saks

et al. 2016

Cancer

View full text Add to dashboard Cite

Background Mesothelium VCAM-1 expression in the metastatic epithelial ovarian cancer (EOC) microenvironment is induced by tumor and mediates tumor cell invasion. VCAM-1 imaging suggests expression during treatment is an indicator of platinum resistance. Here, we assess the potential prognostic significance of mesothelium VCAM-1 expression and prospectively evaluate whether soluble VCAM-1 (sVCAM-1) is a surrogate for mesothelium expression. Methods A retrospective review of EOC patients was performed to evaluate outcomes with mesothelium VCAM-1 expression determined by immunohistochemistry of peritoneum or omentum specimens. A prospective cohort of EOC patients was identified and followed through primary treatment. Serum for sVCAM-1 evaluation, determined by ELISA, was collected prior to surgery or neoadjuvant chemotherapy and at each treatment cycle. Peritoneal specimens were obtained during debulking to assess mesothelial VCAM-1 expression. Results Retrospective review identified 54 advanced stage EOC patients. Patients expressing mesothelium VCAM-1 had shortened overall (44 vs 79 months, p=0.035) and progression-free survival (18 vs 67 months, p=0.010); median time to platinum-resistance was 36 months for VCAM-1 expressing patients and not yet determined for the VCAM-1 negative group. In our prospective observational cohort, eighteen EOC patients completed primary treatment; 3 were negative for mesothelium VCAM-1 expression, and sVCAM-1 did not vary between groups. Conclusions Mesothelium VCAM-1 expression negatively associates with progression-free and overall survival in EOC. This is especially compelling in light of prior data suggesting that persistent VCAM-1 expression during treatment is an indicator of platinum resistance. Our pilot study had insufficient cases to determine whether sVCAM-1 would substitute for mesothelium expression.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Vcam-1 and Ovarian Cancer Outcome/scalici Et Almentioning

confidence: 96%

Mesothelium expression of vascular cell adhesion molecule‐1 (VCAM‐1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC)

Scalici

Arapovic

Saks

et al. 2016

Cancer

View full text Add to dashboard Cite

show abstract

“…The data in this study are derived from a small pilot study, but is representative of our institutional clinical practice in regard to OC histology and stage distribution as well as published pilot studies examining IL-1β in urine, serum, and plasma [17,56,[58][59][60][61] and other clinically relevant pilot studies [62][63][64][65][66]. A normal baseline value for urinary IL-1β in women has not yet been established in the literature [67].…”

Section: Discussionmentioning

confidence: 99%

Urinary interleukin-1ß levels among gynecological patients

Woolery

Hoffman

Kraft

et al. 2014

Journal of Ovarian Research

View full text Add to dashboard Cite

Background: Early detection of epithelial ovarian cancer (OC) is necessary to overcome the high mortality rate of late stage diagnosis; and, examining the molecular changes that occur at early disease onset may provide new strategies for OC detection. Since the deregulation of inflammatory mediators can contribute to OC development, the purpose of this pilot study was to determine whether elevated urinary levels of Interleukin-1beta (IL-1 beta) are associated with OC and associated clinical parameters. Methods: Urinary and serum levels of IL-1 beta were analyzed by ELISA from a patient cohort consisting of healthy women (N = 10), women with ovarian benign disease (N = 23), women with OC (N = 32), women with other benign gynecological conditions (N = 22), and women with other gynecological cancers (N = 6). Results: Average urinary IL-1 beta levels tended to be elevated in ovarian benign (1.26 pg/ml) and OC (1.57 pg/ml) patient samples compared to healthy individuals (0.36 pg/ml). Among patients with benign disease, urinary IL-1β levels were statistically higher in patients with benign inflammatory gynecologic disease compared to patients with non-inflammatory benign disease. Interestingly, urinary IL-1 beta levels tended to be 3-6x greater in patients with benign ovarian disease or OC as well as with a concomitant family history of ovarian and/or breast cancer compared to similar patients without a family history of ovarian and/or breast cancer. Lastly, there was a pattern of increased urinary IL-1 beta with increasing body mass index (BMI); patients with a normal BMI averaged urinary IL-1 beta levels of 0.92 pg/ml, overweight BMI averaged urinary IL-1 beta levels of 1.72 pg/ml, and obese BMI averaged urinary IL-1 beta levels of 5.26 pg/ml. Conclusions: This pilot study revealed that urinary levels of IL-1 beta are elevated in patients with epithelial OC supporting the thought that inflammation might be associated with cancer progression. Consequently, further studies of urinary IL-1 beta and the identification of an inflammatory profile specific to OC development may be beneficial to reduce the mortality associated with this disease.

show abstract

“…One such protein has been Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1). 3 Its elevated concentration is shown to be associated with tumor presence. 4 Expressed on activated endothelial and mesothelial cells VCAM-1 has been identified as an important mediator for adhesion of ovarian cancer cells to and invasion through the mesothelium.…”

Section: Introductionmentioning

confidence: 99%

High Preoperative Serum sVCAM-1 Concentration as a Predictor of Early Ovarian Cancer Recurrence

Jakimovska

Černe

Verdenik

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Role of soluble vascular cell adhesion molecule-1 (sVCAM-1) in ovarian cancer is largely unclear. It was shown that mesothelial expression mediates tumour cell invasion and is associated with metastases in advanced ovarian cancer.Results: Mean sVCAM-1 serum concentration in all patients before operation was 1564.68 ± 435.65 ng/ml while mean ascites level was 801.84 ±244.35 ng/ml. Follow up period was minimum 27 and the maximum 58 months. Patients were divided in two groups according to time to recurrence. Group A: 20 patients with disease progress or relapse within 12 months (mean serum level 1660.54±417.93 ng/ml; mean ascites level 827.92±290.36) and group B: 17 patients with tumour relapse after more than 12 months (mean serum level 451.91±441.15ng/ml; mean ascites level 771.16±179.93). There was statistically significant difference in serum concentration and not in ascites concentrations of sVCAM-1, grade, histology and stage and tumour between the groups. There was a correlation between serum and ascites concentrations in group A and not in the patients from group B. Increased sVCAM-1 concentration in serum and ascites relates to advance ovarian cancer.Conclusions: This is the first study demonstrating that higher serum sVCAM-1 concentrations at the time of diagnosis might be predictive for early relapse. Serum sVCAM-1 can be potential marker for ovarian cancer follow-up.

show abstract

Circulating serum sVCAM-1 concentration in advanced ovarian cancer patients: correlation with concentration in ascites

Cited by 9 publications

References 28 publications

Mesothelium expression of vascular cell adhesion molecule‐1 (VCAM‐1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC)

Mesothelium expression of vascular cell adhesion molecule‐1 (VCAM‐1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC)

Urinary interleukin-1ß levels among gynecological patients

High Preoperative Serum sVCAM-1 Concentration as a Predictor of Early Ovarian Cancer Recurrence

Contact Info

Product

Resources

About